Big Pharma Cuts, Current and Coming

| April 22, 2019

article image
Word came out just before the weekend (first at Endpoints) that GlaxoSmithKline is laying off R&D employees at both Stevenage (UK) and Upper Providence (US). Current leadership is re-organizing drug discovery efforts to put more emphasis on oncology, immunology and genetic-linked disease, and this moves seems linked to that. Reports are that overall R&D head count is supposed to increase as the strategy takes effect, but (as usual) it’s a lot easier to identify people and positions that don’t fit than it is to hire in people that you think do. John Carroll’s sources told him that chemistry is getting hit particularly hard in this round, actually.

Spotlight

Nanomi

Over Nanomi: Nanomi ontwikkelt Nano en Microdeeltjes voor de farmaceutische industrie door middel van onze microfluidic Monosphere Technology. Wij zijn het “center of excellence for complex injectables” van Lupin ltd, een internationaal Indiaas farmaceutisch concern. Nanomi is een internationale, hightech omgeving met een leuke, informele werksfeer. Company Profile: Nanomi, based in Oldenzaal, is a drug delivery company developing pharmaceutical products based on nano- and microparticles. These particles are developed by using Nanomi’s microfluidic Monosphere Technology, enabling the manufacturing of very unique and uniform custom-made particles for a broad range of pharmaceutical products. In 2014 Nanomi was acquired by Lupin and became its center of excellence for complex injectables. Nanomi offers a highly innovative as well as dynamic environment and benefits from its parent company that was founded in 1968. Lupin is an innovation led transnational pharmaceutical company developing

OTHER ARTICLES

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 9, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Spotlight

Nanomi

Over Nanomi: Nanomi ontwikkelt Nano en Microdeeltjes voor de farmaceutische industrie door middel van onze microfluidic Monosphere Technology. Wij zijn het “center of excellence for complex injectables” van Lupin ltd, een internationaal Indiaas farmaceutisch concern. Nanomi is een internationale, hightech omgeving met een leuke, informele werksfeer. Company Profile: Nanomi, based in Oldenzaal, is a drug delivery company developing pharmaceutical products based on nano- and microparticles. These particles are developed by using Nanomi’s microfluidic Monosphere Technology, enabling the manufacturing of very unique and uniform custom-made particles for a broad range of pharmaceutical products. In 2014 Nanomi was acquired by Lupin and became its center of excellence for complex injectables. Nanomi offers a highly innovative as well as dynamic environment and benefits from its parent company that was founded in 1968. Lupin is an innovation led transnational pharmaceutical company developing

Events